文献速递垂体与肾上腺疾病性腺与生殖内分泌

乌利司他醋酸酯抑制糖皮质激素受体活性

The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究探讨选择性孕激素受体调节剂乌利司他醋酸酯是否影响糖皮质激素受体活性。在子宫肌瘤细胞、肝细胞、原代肌瘤组织及小鼠体内实验中,乌利司他呈剂量依赖性阻断糖皮质激素转录反应,抑制GR磷酸化、核转位及DNA结合,并在肺、肝、子宫降低糖皮质激素反应基因表达,但在海马和垂体升高Fkbp5和Gilz转录水平。

要点

  • 乌利司他剂量依赖性抑制糖皮质激素靶基因PER1、FKBP5、GILZ的转录反应。
  • 乌利司他阻断GR磷酸化、核转位及DNA结合,在肌瘤组织和肝细胞中均观察到。
  • 小鼠体内2 mg/kg乌利司他降低肺、肝、子宫糖皮质激素反应基因表达,但升高海马和垂体Fkbp5、Gilz转录水平。

核心结论

  • 乌利司他抑制人肌瘤细胞和肝细胞的内源性糖皮质激素信号,长期用药时需考虑这一相互作用。

研究设计与样本

  • 永生化人子宫肌瘤细胞(UtLM)和肝细胞(HepG2)用合成糖皮质激素地塞米松和/或乌利司他处理。
  • 原代子宫肌瘤组织取自择期妇科手术患者,离体用地塞米松和/或乌利司他处理。
  • C57Bl/6小鼠体内暴露于乌利司他,检测全身靶组织基础基因表达变化。

主要发现

  • 地塞米松诱导UtLM和HepG2细胞中PER1、FKBP5和GILZ表达,乌利司他共处理呈剂量依赖性阻断该转录反应。
  • 乌利司他抑制糖皮质激素介导的GR磷酸化、核转位和DNA相互作用。
  • 原代子宫肌瘤组织中,乌利司他共处理废除地塞米松对PER1、FKBP5和GILZ的刺激。
  • 暴露于2 mg/kg乌利司他的小鼠,肺、肝和子宫中糖皮质激素反应基因表达降低。
  • 小鼠海马和垂体中Fkbp5和Gilz转录水平升高。

临床怎么用

  • 长期使用乌利司他治疗子宫肌瘤时,应关注其抑制糖皮质激素受体活性可能带来的全身效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The selective progesterone modulator ulipristal acetate (ulipristal) offers a much-needed therapeutic option for the clinical management of uterine fibroids. Although ulipristal initially passed safety evaluations in Europe, postmarketing analysis identified cases of hepatic injury and failure, leading to restrictions on the long-term use of ulipristal. One of the factors potentially contributing to significant side effects with the selective progesterone modulators is cross-reactivity with other steroid receptors. OBJECTIVE: To determine whether ulipristal can alter the activity of the endogenous glucocorticoid receptor (GR) in relevant cell types. DESIGN: Immortalized human uterine fibroid cells (UtLM) and hepatocytes (HepG2) were treated with the synthetic glucocorticoid dexamethasone and/or ulipristal. Primary uterine fibroid tissue was isolated from patients undergoing elective gynecological surgery and treated ex vivo with dexamethasone and/or ulipristal. In vivo ulipristal exposure was performed in C57Bl/6 mice to measure the effect on basal gene expression in target tissues throughout the body. RESULTS: Dexamethasone induced the expression of established glucocorticoid-target genes period 1 (PER1), FK506 binding protein 51 (FKBP5), and glucocorticoid-induced leucine zipper (GILZ) in UtLM and HepG2 cells, whereas cotreatment with ulipristal blocked the transcriptional response to glucocorticoids in a dose-dependent manner. Ulipristal inhibited glucocorticoid-mediated phosphorylation, nuclear translocation, and DNA interactions of GR. Glucocorticoid stimulation of PER1, FKBP5, and GILZ was abolished by cotreatment with ulipristal in primary uterine fibroid tissue. The expression of glucocorticoid-responsive genes was decreased in the lung, liver, and uterus of mice exposed to 2 mg/kg ulipristal. Interestingly, transcript levels of Fkbp5 and Gilz were increased in the hippocampus and pituitary. CONCLUSIONS: These studies demonstrate that ulipristal inhibits endogenous glucocorticoid signaling in human fibroid and liver cells, which is an important consideration for its use as a long-term therapeutic agent.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Small B, Millard CEF, Kisanga EP, et al. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor. J Clin Endocrinol Metab. 2020. PMID: 31665442. doi:10.1210/clinem/dgz139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。